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Medulloblastoma, the most common malignant pediatric brain tumour, arises in the 
cerebellum, and disseminates through the cerebrospinal fluid (CSF) in the leptomeningeal 
space to coat the brain and spinal cord1. Dissemination, a marker of poor prognosis, is found 
in up to 40% of children at diagnosis and most children at the time of recurrence. Therefore, 
affected children are treated with radiation to the entire developing brain and spinal cord 
followed by high dose chemotherapy with ensuing deleterious effects on the developing 
nervous system 2. The mechanisms of CSF dissemination are poorly studied and 
medulloblastoma metastases have been assumed to be biologically similar to the primary 
tumour 3,4. Here we show that in both mouse and human medulloblastoma, multiple 
metastases from a single patient are extremely similar to each other, but divergent from the 
matched primary tumour. Clonal genetic events in the metastases can be demonstrated in a 
restricted sub-clone of the primary tumour, suggesting that only rare cells within the primary 
tumour have the ability to metastasize. Failure to account for the bicompartmental nature of 
metastatic medulloblastoma could represent a major barrier to the development of effective 
targeted therapies.
Thirty percent of Ptch+/− mice develop non-disseminated medulloblastoma by eight months 
of age5. Recently, the Sleeping Beauty (SB) transposon system was shown to be an effective 
tool for functional genomics studies of solid tumour initiation and progression 6,7. We 
expressed the SB11-transposase in cerebellar progenitor cells in transgenic mice under the 
Math1 enhancer/promoter, but did not observe any tumours when bred to transgenic mice 
with a concatemer of the T2/Onc transposon (Fig. 1, Supplemental Fig. S1, S2)8. However, 
Ptch +/−/Math1-SB11/T2Onc mice showed increased penetrance of medulloblastoma 
(~100% (271 out of 279) compared to ~40% (54 out of 139) of controls, and decreased 
latency (8 months to 2.5 months) (Fig. 1, Supplemental Fig. S2). While Ptch +/− 
medulloblastomas are usually localized, the addition of SB transposition results in metastatic 
dissemination through the CSF pathways, identical to the pattern seen in human children 
(Fisher’s exact test, p=1.8e-07, odds ratio=5.2, Supplemental Table S1) (Fig. 1c, d, g, h, 
Supplemental Figure S2). As neither transposon, nor transposase alone had an effect on 
tumour incidence, latency, or dissemination, we conclude that SB-induced insertional 
mutagenesis drives medulloblastoma progression on the Ptch +/− background (Fig. 1i, 
Supplemental Fig. S2).
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Humans with germline mutations in TP53 have Li-Fraumeni syndrome and are at increased 
risk to develop medulloblastoma. While no medulloblastomas were found in Tp53mut (Tp53
+/−
 or Tp53−/−) mice, 40% of Tp53mut/Math1-SB11/T2Onc mice developed disseminated 
medulloblastoma (Fig. 1e–h, j, Supplemental Fig. S2)9. Human medulloblastomas with 
TP53 mutations frequently have large cell/anaplastic histology. Tp53mut/Math1-SB11/T2Onc 
medulloblastomas exhibit large cells, nuclear atypia, and nuclear molding typical of large 
cell/anaplastic histology (Fig. 1f). We conclude that SB transposition can drive the initiation 
and progression of metastatic medulloblastoma on a Tp53mut background.
We used linker-mediated PCR and Roche 454 sequencing to identify the site of T2/Onc 
insertions in Ptch+/−/Math1-SB11/T2Onc, and Tp53mut/Math1-SB11/T2Onc primary 
medulloblastomas and their matched metastases. Genes that contained insertions statistically 
more frequently than the background rate were identified as gene-centric commonly inserted 
sites (gCISes)10. We identified 359 gCISes from 139 primary tumours on the Ptch 
background and 26 gCISes from 36 primary medulloblastomas on the Tp53 background 
(Supplemental Tables S2–S7, Supplemental Figures S3–S5). A large number of gCISes 
targeted candidate medulloblastoma oncogenes/tumour suppressor genes (Supplemental 
Table S8)11. Insertions in candidate tumour suppressor genes including EHMT1, CBP, and 
MXI1 are predicted to be loss of function (Fig. 1k,l,m), while insertions in putative 
medulloblastoma oncogenes are largely gain of function, as exemplified by MYST3 (Fig. 
1n).
Many gCISes mapped to regions of amplification, focal hemizygous deletion, and 
homozygous deletion, which we recently reported in the genome of a large cohort of human 
medulloblastomas (Supplemental Table S8) 11. There is a high level of overlap between 
gCISes and known cancer genes (COSMIC database) (Supplemental Table S9,10), 
suggesting that many gCISes are bona fide driver genes in medulloblastoma (Fisher’s exact 
test p=0.0012)12. Similarly, many mouse gCIS/ human amplified genes are over-expressed 
in human Shh medulloblastomas (Supplemental Fig. S6). Conversely, mouse gCISes deleted 
in human medulloblastomas were frequently expressed at a lower level in human 
medulloblastomas (Supplemental Fig. S6). Expression of 6/7 gCISes studied by 
immunohistochemistry on a human medulloblastoma tissue microarray were associated with 
a significantly worse overall and progression free survival in human medulloblastoma 
(Supplemental Table 11, Supplemental Figures S7, S8) 13. We conclude that our SB-driven 
leptomeningeal disseminated medulloblastoma model resembles the human disease 
anatomically, pathologically and genetically and thus represents an accurate model of the 
human disease that can be used to identify candidate driver events and understand the 
pathogenesis of human medulloblastoma.
We compared the gCISes identified from Ptch+/−/Math1-SB11/T2Onc, and Tp53mut/Math1-
SB11/T2Onc primary medulloblastomas and matched metastases (Supplemental Table S2). 
Strikingly, the overlap between primary tumour gCISes (pri-gCISes) from Ptch+/−/Math1-
SB11/T2Onc tumours and those from the metastases (met-gCISes) from the same animals 
was only 9.3% of gCISes (Figure 2a). Similarly, the overlap in pri-gCISes from primary 
Tp53mut/Math1-SB11/T2Onc gCISes and the matching met-gCISes was only 8.9% (Figure 
2b). Leptomeningeal metastases and the matched primary tumour share identical, highly 
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clonal insertion sites (Fig. 2c). The chances of two (or three) unrelated tumours having SB 
insertions in exactly the same TA dinucleotide are extremely low. We conclude that 
leptomeningeal metastases and matched primary tumour arise from a common transformed 
progenitor cell, and have subsequently undergone genetic divergence. Sequencing also 
identified insertions that are highly clonal in the metastases, but not seen in the matched 
primary tumour (not shown). Endpoint PCR for these insertions in the matched primary/
metastatic tumours show that the insertion is highly clonal in the metastase(s), and present in 
a very small subclone of the primary tumour (Fig. 2d, Supplemental Figure S9). These data 
are consistent with a model in which metastatic disease arises from a minor restricted 
subclone of the primary tumour. Dissemination could occur repeatedly from the same 
subclone of the primary tumour, which seeds the rest of the CNS, or could occur once 
followed by reseeding of the rest of the leptomeningeal space by the initial metastasis. 
Insertions that are restricted to a minor subclone of the primary tumour, but which are clonal 
in the metastases, could correspond to the ‘metastasis virulence’ genes, described 
previously, that offer a genetic advantage during dissemination, but not to the primary 
tumour 14. Another explanation of our data could be reseeding of the primary tumour by a 
metastatic clone that had acquired additional genetic events in the periphery. This latter 
hypothesis is mitigated by the presence in the same animal of highly clonal insertions in the 
metastasis that are completely absent from the primary tumour 15. As reseeding should be 
accompanied by contamination of the primary tumour with events found in the metastases, 
absence of these events in the matched primary tumour makes reseeding much less likely 
(Fig. 2e). We hypothesize that events found only in one metastasis represent progression 
events acquired post-metastasis, and which could lead to localized progression of metastatic 
disease as is sometimes seen in human children. We observed highly clonal insertions in the 
primary tumour, including known medulloblastoma oncogenes such as Notch2, or Tert, 
which are not found in the matching metastases (Fig. 2f). This pattern could be explained 
through remobilization of the SB transposon in the metastatic tumour; however, no signs of 
the DNA footprint left after SB remobilization at these loci were observed (Supplemental 
Fig. S10)16. We suggest that these events, which may constitute driver events in the primary 
tumour, have arisen in the primary tumour after the metastases have disseminated (post-
dispersion events). Although these known oncogenes represent attractive targets for therapy, 
their utility as targets for therapy may be limited if the target is not also found in the 
leptomeningeal compartment of the disease. Our data from two separate mouse lines 
supports a model in which medulloblastoma disseminates early from a restricted subclone of 
the primary tumour, and where the primary tumour and the matched metastases then 
undergo differential clonal selection and evolution. Failure to account for the differences 
between the primary and leptomeningeal compartments could lead to the failure of targeted 
therapies. Failure to study the leptomeningeal disease could result in systematically 
overlooking critical targets for therapy in this compartment (Fig. 2e).
Examination of met-gCIS genes using GSEA demonstrates differences between the primary 
and metastatic disease, which importantly include enrichment for genes involved in the 
cytoskeleton among the metastases (Supplemental Table S12). Targets that are present in 
both compartments, and which are maintenance genes, will be optimal targets for therapy of 
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both the primary and metastatic compartments, as exemplified by Pdgfra (Fig. 2c, 
Supplemental Tables S7, S9).
Pten, Akt2, Igf2, and Pik3r1 are all met-gCISes, implicating the PI3-kinase pathway in 
medulloblastoma progression. We injected the cerebella of Nestin-TVA mice 17 with either 
Shh virus alone, or Shh + Akt virus. Cerebellar injection of Shh alone resulted in 
medulloblastoma in 6/41 animals, compared to 20/42 animals injected with Shh + Akt 
(p=0.0018). Poignantly, while metastases were never seen with Shh virus alone (0/41), 
medulloblastoma metastases were seen in 9/42 animals injected with Shh + Akt (p=0.0024) 
(Supplemental Fig. S11). In vivo modeling validates PI3-kinase signaling and suggests that 
it can contribute to leptomeningeal dissemination of medulloblastoma.
Prior publications and clinical approaches to human medulloblastoma have largely assumed 
that the primary tumour and its matched metastases are highly similar 3,4. To test this 
assertion we formally reviewed all cases of medulloblastoma from the last decade at The 
Hospital for Sick Children, and identified 19 patients who had both bulk residual primary 
tumour post-surgery, and MRI visible metastases, both of which could be followed for 
response to treatment in the two compartments (Supplemental Fig. S12 and Supplemental 
Table S13). While it is possible that metastases might have received reduced radiotherapy 
than the primary tumor in a subset of patients, in 58% of overall cases (11/19) we observed a 
disparate response to therapy between the primary tumor and matched metastases (binomial 
test, p<2.2e-16). Identification of definitive differences in the clinical response to standard 
therapy between the primary and metastatic compartment awaits the completion of large, 
well controlled, prospective clinical trials.
We examined seven matched primary/metastatic medulloblastomas for copy number 
aberrations (Fig. 3, Supplemental Figures S13, S14, Supplemental Tables S14, S15). In each 
case, the primary tumour and the matched metastases share complicated genetic events that 
highly support descent from a common transformed progenitor cell. Similar to our mouse 
data, in each case we see clonal genetic events in the metastatic tumour(s) that are not 
present in the matched primary tumour (Fig. 3. Supplemental Fig. S14). We also observe 
genetic events in the primary tumour that are absent from the matched metastasis, consistent 
with a ‘post-dispersion event’ (Fig. 3, Supplemental Fig. S14). Examination of a case with 
multiple leptomeningeal metastases demonstrates a deletion of chromosome 1p in only 1/3 
metastases (Fig. 3a). This pattern of genetic events that are present only in a subset of 
metastases could be a mechanism for the emergence of therapy resistant metastatic clones.
We performed interphase FISH for the known medulloblastoma oncogenes MYCN and MYC 
on a collection of 17 paraffin embedded primary/metastatic pairs of human 
medulloblastoma 18–20. MYCN was amplified in 3 primary medulloblastomas, but not in the 
matching metastases (Fig. 3b, Supplemental Fig. S15). Conversely, MYC was amplified in 2 
primary tumours and their matching metastases (Fig. 3c). These data are consistent with 
MYCN amplification being a ‘post-dispersion’ event, similar to examples in SB driven 
mouse medulloblastoma, and highly suggest that anti-MYCN therapeutics could lack 
efficacy in the metastatic compartment of human medulloblastoma. The possibility that 
MYCN amplicons are ‘lost’ overtime in the metastases cannot be excluded.
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We subsequently analyzed promoter CpG-methylation in these matched pairs and found that 
there was a great deal of discordance between the primary tumour and matched metastases 
(Fig. 3d, Supplemental Figures S13, S16, Supplemental Tables S16–17). Finally, we 
performed whole-exome sequencing on a limited set of matched primary/metastatic 
medulloblastomas, and found many single nucleotide variants (SNVs) that were restricted to 
one compartment or the other (Supplemental Fig. S13, Supplemental Table S18). 
Discordance of CNAs, promoter CpG methylation events, and SNVs between the primary 
tumour and its matched metastases supports a bicompartmental model for metastatic 
medulloblastoma. The mutational load in the human tumours (combination of CNAs, CpG 
methylation, and SNVs) compares favorably to the mutational load in our transposon driven 
mouse models (median number of gCISes=25 per tumour, Supplemental Table S19). 
Validation of individual CNAs restricted to the metastases, reveals that they can be detected 
in a very minor subclone of the primary tumour, in keeping with the relationship identified 
in the mouse model (Supplemental Fig. S17, Supplemental Table S20–21). Pathway analysis 
using DAVID to compare mouse gCISes with genes affected in human metastases identified 
only a single statistically significant shared signaling pathway – insulin signaling (p=0.027) 
(Supplemental Table S22). The known role for insulin receptor signaling in primary 
medulloblastoma21, and the data presented above on the role of Akt in metastatic 
medulloblastoma, might suggest prioritization of insulin signaling as a therapeutic target to 
be tested in clinical trials.
We performed unsupervised hierarchical clustering on CpG methylation data revealing that 
normal cerebellar controls cluster away from the medulloblastomas, while metastases 
clustered with their matching primary tumour (Fig. 4a). However, metastases cluster more 
closely to each other than they do to the matched primary tumour (z-test, p=0.0014, 
Supplemental Fig. S18). Unsupervised hierarchical clustering of CNA and exome SNV data 
reveals the same relationships (Fig. 4b,c). Evident within the exome data are many events 
that are shared only by patient matched metastases, as well as events restricted to the 
primary tumour, both of which are similar to the genetic patterns observed in the mouse. 
These three data sets support a model in which patient matched human medulloblastoma 
metastases are epigenetically, and genetically very similar to each other, but have 
substantially diverged from their primary tumour, resulting in two different disease 
compartments: primary and metastatic.
Our data from two different mouse models with support by initial data from human 
medulloblastoma suggests that leptomeningeal metastases of medulloblastoma from a single 
human/mouse are genetically similar to each other, but highly divergent from the matched 
primary tumour, consistent with a bicompartmental model of the disease. Our results are 
consistent with a model in which metastases arise from a restricted subclone of the primary 
tumour through a process of clonal selection in both humans and mice. That metastases 
might arise from a pre-existing minor subclone of the primary tumour through clonal 
selection was suggested more than three decades ago, but remains a controversial hypothesis 
whose truth may vary from one disease to another 22–25. Failure to account for the divergent 
molecular pathology of the metastatic compartment may result in selection of therapeutic 
targets present in the primary tumour (which is more amenable to surgical control) and not 
the metastases, which are the more frequent cause of death.
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Methods Summary
Generation of Math1SB11 transposase transgenic mouse
SB11 transposase cDNA was excised from pCMV-SB11 and ligated into J2QMath1 
vector268.
Linker-mediated PCR and 454 deep sequencing
Bar-coded, linker-mediated PCR was performed as previously described 6. Sample 
preparation for 454 sequencing and subsequent procedures were performed as described 27.
Determination of gCISes: Gene-centric common insertion site analysis
A chi-square analysis was performed to determine if the number of observed integration 
events within each transcription unit in the SB driven medulloblastomas is significantly 
greater than expected given the number of TA dinucleotide sites within the gene relative to 
the number of TA sites in the genome, the number of integration sites within each tumour 
and the total number of tumours in each cohort. This gene-centric common insertion site 
(gCIS) analysis produced a p-value for each of the ~19,000 mouse RefSeq genes, and 
therefore Bonferroni correction was used to adjust for multiple-hypothesis testing.
Methods
Linker-mediated PCR and 454 deep sequencing
Genomic DNA was isolated and purified from mouse tissues with DNeasy Tissue and Blood 
kit (QIAGEN). The subsequent bar-coded linker-mediated PCR was performed as 
previously described. Sample preparation for 454 sequencing and subsequent procedures 
were performed as described 27.
PCR for SB-tagged fragments
Primers for amplifying SB transposon insertion sites were designed based on chromosomal 
location of each independent insertion site and its orientation to the transcription. The 
primers at IRDRL and IRDRR of the transposon are: 5′-
CTGGGAATGTGATGAAAGAAATAAAA-3′ and 5′-TTGTGTCATGCACAAAGTAGATGT -3′, 
respectively. The input represents genomic DNA with SB transposition, which was 
illustrated by SB excision PCR that detect the transposon at post-transposition 6. Three 
points of input (1x, 5x, 25x) were used. Details about primer design for specific insertion 
sites and the PCR protocol are available upon request.
Review of Clinical Cases
We systematically reviewed all cases of medulloblastoma seen at the Hospital for Sick 
Children over the past ten years. Cases were identified that have both metastases and post-
operative residual bulky disease at the primary site on the basis of postoperative imaging 
obtained within 72 hours of surgery. All radiology was reviewed by a senior neuro-
oncologist (EB). Objective responses of both the primary tumor, and the metastatic disease 
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were measured using the International Society for Pediatric Oncology (SIOP) criteria that 
are standard for clinical trials of pediatric brain tumors 28.
End-point PCR on human samples
For PCRs to confirm the deletion of CDKN2A locus at chromosome 9, a genome-walking 
approach (GenomeWalker Universal kit, Clonetech Cat#638904) was taken to locate the 
specific deletion region based on SNP coordinates. Primers flanking the deletion region are: 
Forward 5′-GCAATTAACCAAGACCACCCAATGGCAAG-3′ and Reverse 5′-
GTAGCTATTGGGGAGGTTGAGAAGGAG-3′. Three points of input shown as ACTB (1x, 
5x, 25x) were used. The PCR products were inserted into pCR2.1 TA cloning vector 
(Invitrogen), sequenced and blasted against human genome to confirm the deletion. For 
REXO1L1 deletion at chromosome 8, specific primers flanking the deletion region were 
designed based on SNP microarray results. The PCR products were TA-cloned and 
sequenced as described above. The primers are: Forward 5′-GGCTGACTCCCTTCT 
GATATAG-3′ and Reverse 5′-CAA TCA CTT ACA GTT ACT AGG CAC-3′. Details about the 
primer design and PCR protocols are available upon requested.
Chromosomal mapping of gCISes
Chromosomal maps of gCISes-associated genes were obtained from UCSC Mouse Genome 
Browser (assembly in July 2007). Each insertion site of a specific CIS was mapped to the 
gene with the same orientation as transcription (arrow in green) or inverse (arrow in red) to 
the direction of transcription.
Human medulloblastoma tumour specimens
All tumour specimens were obtained in accordance with the Research Ethics Board at the 
Hospital for Sick Children (Toronto, Canada). Surgically-resected, fresh-frozen samples 
were obtained from the Co-operative Human Tissue Network (Columbus, OH), and the 
Brain Tumor Tissue Bank (London, Canada).
SB remobilization
Potential SB insertion sites either at Fubp1, Mnat1 and Igf2 in primary tumours from 
mouse#143, #14 and 112, or at Ptges, Aof1 and Notch2 in the matched spine mets were 
tested for remobilization. Primers were designed to amplify each insertion site to produce a 
proximate 300bp with the insertion site in the middle. PCR products were either sequenced 
directly or after being TA-cloned. The resulted sequences were examined for ‘scars’ from 
potential remobilization. As positive controls for the ‘scars’, primers were used to amplify 
T2Onc transposon in each samples8. The products were sequenced and examined for the 
‘scars’ as described above. Details about the primer design and PCR protocols are available 
upon requested.
Hierarchical clustering
Agglomerative hierarchical clustering analyses were performed in the R statistical 
programming environment (v2.13). The average linkage method was used in all cases. As 
different data types were used in the various analyses, the metric used for clustering differed 
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among analyses. Manhattan distance metric was used for the copy number data, since the 
data was encoded as {−1, 0, 1}. The magnitudes of the copy number aberrations (CNAs) 
were not considered, due to multitude of confounding factors including tumour 
heterogeneity and ploidy. Kendall correlation was used for the single nucleotide variant 
(SNV) frequency data, since the data distributions were not normal. Pearson correlation was 
used for the methylation data, which were normally distributed.
Identification of CpG Hypermethylation Events—Human genomic DNA was 
isolated from matching primary and metastatic medulloblastomas obtained from John 
Hopkins University, Virginia Commonwealth University and New York University. 
Zymogen’s EZ DNA Methylation kit was employed for bisulfite-converting 500ng of each 
sample. The recovered DNA was profiled on Illumina HumanMethylation27 BeadChips at 
TCAG. Subsequently 27,578 CpG dinucleotides spanning 14,495 genes were analyzed. 
Probe signal intensity was corrected by using Illumina BeadStudio 3.2.0 software. The 
background normalization and differential methylation analyses were performed against 
fetal cerebella by Illumina Custom Error Model. Cancer-specific DNA hypermethylation 
events were defined as those with a 30% increase in methylation in at least one 
medulloblastoma samples, relative to an average methylation level (less than 50%) in 
normal fetal and adult cerebellum samples. An unsupervised clustering using Euclidian 
hierarchical clustering metrics was then performed on 2503 data points that were filtered for 
cancer-specific hypermethylation events. CpG methylation data is available from GEO 
under GSE 34356.
Bisulfite sequencing CpG promoter methylation
Representative examples of primary- and metastatic-specific methylation events were 
identified from normalized Illumina Hg27 methylation data. Bisulfite PCR (BSP) primers 
were designed using Sequenom Epidesigner tool (http://www.epidesigner.com/) 
encompassing a genomic region flanking the Illumina Hg27 gene-specific probe. 500ng of 
primary and corresponding metastatic DNA were bisulfite converted using EZ DNA 
Methylation Kit (Zymo Research). Following PCR optimization, 10ng of bisulfite converted 
DNA was used to amplify genomic regions of interest. Amplicons were subcloned into 
pCR2.1-TOPO (Invitrogen) and plasmid DNA from 10–12 colonies was extracted using 
Purelink Quick Plasmid Miniprep Kit (Invitrogen). Sequencing was performed at the TCAG 
using the M13 Reverse primer (5′-CAG GAA ACA GCT ATG AC). Details about the 
primer design and PCR protocols are available upon requested.
Alignment and variant calling for whole exome sequencing
Standard manufacturer protocols were used to perform target capture with the Illumina 
TruSeq exome enrichment kit and sequencing of 100 bp paired end reads on Illumina Hiseq. 
Approximately 10 Gb of sequence were generated for each subject such that >90% of the 
coding bases of the exome defined by the consensus coding sequence (CCDS) project were 
covered by at least 10 reads. Adaptor sequences and quality trimmed reads were removed by 
using the Fastx toolkit (http://hannonlab.cshl.edu/fastx_toolkit/) and then a custom script 
was used to ensure that only read pairs with both mates present were subsequently used. 
Reads were aligned to hg19 with BWA1, and duplicate reads were marked using Picard 
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(http://picard.sourceforge.net/) and excluded from downstream analyses. Single nucleotide 
variants (SNVs) and short insertions and deletions (indels) were called using samtools 
(http://samtools.sourceforge.net/) pileup and varFilter2 with the base alignment quality 
(BAQ) adjustment disabled, and quality filtered to require at least 20% of reads supporting 
the variant call. Variants were annotated using both Annovar3 and custom scripts to identify 
whether they affected protein coding sequence, and whether they had previously been seen 
in dbSNP131, the 1000 genomes pilot release (Nov. 2010), or in approximately 160 exomes 
previously sequenced at our center.
SNV analysis of whole Exome sequencing data
For clustering analysis, a SNV frequency matrix was constructed by calculating frequencies 
from the read counts of the reference and the alternative nucleotide. The matrix was not 
standardized (i.e. converted to z-scores) prior to clustering, since the absolute SNV 
frequencies were of interest.
For Venn analysis, the samples were grouped into primary-metastasis sets, and the filtered 
SNVs were used to identify SNVs that are enriched in one sample compared to all other 
samples of the same set, as determined by the hypergeometric test (p-value threshold = 
0.05). For sets consisting of three or more samples (A, B, and C), a SNV was considered to 
be enriched in samples A and B if the SNV was enriched in A as compared to C alone and 
also enriched in B as compared to C alone. SNVs that were not enriched in any sample or 
subsets of samples were considered to be common SNVs. Many of these common SNVs 
likely represented germline SNVs specific to the patient.
Analysis of CpG promoter methylation data
The similarities between patient-matched metastatic and primary tumour samples and 
between patient-matched metastatic tumour samples were determined by using Pearson 
correlation analysis. As Pearson’s r values are not normally distributed, they were 
standardized by Fisher’s z transformation. Subsequently, the correlations between metastatic 
samples and the matched primary samples were compared to the correlations between the 
patient-matched metastatic samples, using the paired heteroscedastic Student’s t test. 
Clustering analysis was performed as described above. The methylation matrix was not 
standardized prior to clustering, as doing so would discard critical information regarding the 
differences in overall methylation profiles among samples or average methylation among 
CpG promoters.
The stability of the CpG hypermethylation profile clusters was assessed using three 
methods. First, the clustering analysis was run for different numbers of CpG 
hypermethylation sites that vary most widely among samples. The partitions generated by 
each clustering run is compared to the reference partitions generated by original clustering 
based on the 1000 most variable hypermethylated CpG islands using the Jaccard similarity 
index. The same analysis was applied to a set of 100 background hypermethylation data 
matrices in which the sites are permuted within and independently for each sample. Second, 
the clustering analysis was performed for random sub-samples of 1000 sites, for 1000 repeat 
runs. In each run, the resulting cluster was compared to the original cluster using the Jaccard 
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index. Analysis on the original data matrix was compared to a set of 100 background 
matrices, permuted as described above. Third, the cluster stability was further assessed by 
bootstrap re-sampling of the samples using the Pvclust R package (v1.2).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Transposon mutagenesis models disseminated human medulloblastoma
Histology of transposon driven medulloblastoma on the Ptch +/− background (a to d) 
resembles human medulloblastoma with leptomeningeal metastases on the surface of the 
brain (c) and spinal cord (d). Histology of transposon driven medulloblastoma on the 
Tp53 mut background (e to h) show histological features of large cell/anaplastic 
medulloblastoma including nuclear pleomorphism and nuclear wrapping (f). Dissemination 
to the leptomeningeal spaces of the brain (g) and spinal cord (h). (i) Ptch +/− mice with 
sleeping beauty transposition develop more frequent medulloblastomas with a shorter 
latency than Ptch +/− mice without transposition (P values are from t-tests of survival 
comparing individual genotypes to Ptch +/− mice; n= # of mice per genotype). (j) 
Medulloblastoma was not seen in Tp53mut mice without transposition, but was seen in 42% 
of Tp53mut mice with transposition. (P values are from t-tests comparing survival between 
Tp53mut mice and SB11-T2Onc-Tp53mut and Tp53mut mice; n = # of mice). (k–n). Insertion 
maps of notable gCISes. Insertions in the direction of transcription denoted by green arrows, 
those against the direction of transcription by red arrows.
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Figure 2. Transposon driven metastatic medulloblastoma genetically differs from the primary 
tumour
(a,b) Venn diagram showing the extent of overlap between gCISes in primary tumours and 
metastases on the Ptch +/− and Tp53mut backgrounds. (c–f) Insertion site, end point PCR to 
demonstrate relative clonality of insertions between samples. Three levels of input DNA 
were used for each sample as illustrated (1x, 5x, 25x). Insertions in the first column are from 
medulloblastoma #143 (c) Clonal events found in both primary tumour and matching 
metastases. (d) Insertions that are highly clonal in the metastases, but very sub-clonal in the 
matching primary tumour. (e) Insertions that are highly clonal in the metastases, but 
completely undetectable in the matching primary tumour. (f) Insertions that are highly clonal 
in the primary tumour, but completely undetectable in the matching metastases.
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Figure 3. Human medulloblastoma metastases are biologically distinct from their matched 
primary tumour
(a) Copy number data from a primary medulloblastoma and three patient matched 
metastases, with chromosomal regions in red representing genetic gain (amplification), and 
blue denoting genetic loss (deletion). Examples of shared clonal events (red boxes), events 
limited to the metastases (blue boxes), and events limited to one but not all metastases 
(black box) are shown. (b) Interphase FISH shows amplification of MYCN in a primary 
tumour, but not the matched metastasis. (c) Interphase FISH for MYC demonstrates 
amplification in both the primary tumour and its matched metastases. (d) Venn diagrams 
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depicting the degree of overlap and discordance in promoter CpG methylation events 
(above) and copy number alterations (below) in primary medulloblastomas and their 
matched metastasis.
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Figure 4. Human medulloblastoma metastases are genetically distinct from the primary tumour
(a) Profiling the methylation status of 27,578 CpG dinucleotides sites in the human genome 
in a collection of human matched primary and metastatic medulloblastomas, top 2000 genes 
are shown. Unsupervised hierarchical clustering by CpG methylation patterns demonstrates 
that patient matched metastases are more similar to each other than to their matched primary 
tumour. (b) Unsupervised clustering of regions of copy number gain and loss demonstrates 
that patient matched metastases are more similar to each other, than they are to their 
matched primary tumour. (c) Unsupervised hierarchical clustering of SNV data from whole 
exome sequencing demonstrates that patient matched metastases are more similar to each 
other than to the patient matched primary tumour. SNVs that are found only in the primary 
compartment, or only in both tumours in the metastatic compartment are evident.
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